ACO E-bulletin, May 2015. Images not displaying below? Enjoy this online
Ce courriel ne s’affiche pas correctement? Affichez-le dans votre navigateur
|
|
Canadian HIV Vaccine Initiative (CHVI)
Research and Development
Alliance Coordinating Office (ACO)
|
|
|
|
|
|
ACO Annual CHVI R&D Alliance Meeting identifies gaps, addresses complementary and collaborative group initiatives in HIV vaccine research
World-renowned experts in HIV discussed collaborations across sectors and borders at the ACO Annual CHVI R&D Alliance Meeting in Toronto on April 30, 2015. The meeting served to inform Canadian stakeholders on recent highlights and outcomes from national and international HIV vaccine research and development partnerships and collaborations. READ THE HIGHLIGHTS. The ACO will release a report on the meeting in the near future.
|
| |
|
ACO Photo Booth at CAHR 2015 Showcases Sentiments about HIV Vaccines
The ACO had a booth at the CAHR 2015 exhibit where we invited delegates to write down their thoughts on why we need an HIV vaccine. Several people stopped by the booth to fill out statement cards with the phrase, "We need an HIV vaccine because..." Participants had the option of having their photo taken holding their statement cards. ACO collected and displayed the statement cards, showcasing the collection of people's sentiments about the need for an HIV vaccine. SEE PHOTO GALLERY
New Research
|
|
|
|
HIV 'Can-Opener' Molecule Exposes Virus' Most Vulnerable Parts; What It Means For Vaccine Development
Medical Daily, May 5, 2015
While testing a recently developed molecule, JP-III-48, on samples from HIV-positive patients, researchers at the University of Montreal observed something ground breaking. The molecule had the ability to open up HIV “like a flower.” Although this finding is still in its early stages, the team (from Centre hospitalier de l'Université de Montréal [CHUM] Research Centre) hopes it may set the foundation for new preventive HIV measures and even possibly a way to eliminate the virus from those already infected. READ MORE.
Socioeconomic Status and HIV Vaccine Preparedness Studies in North America
Vaccine, Volume 33, Issue 22, May 21 2015, Pages 2536–45
Dhalla S, Poole G
This article is a systematic review of socioeconomic status (SES) variables in North American countries, and their relationship to willingness to participate (WTP) and retention in a hypothetical preventive phase 3 HIV vaccine trial and in actual HIV vaccine trials. The research team from the University of British Columbia found that in large part, there was no relationship between educational level and WTP, as well as between educational level and retention. Similarly, there was no relationship between employment and WTP. READ MORE.
Canadian HIV Vaccine Initiative (CHVI) Interactive Projects Map
The CHVI's Interactive Projects Map highlights recipients of CHVI funding around the world and visual guide to some of Canada's contribution to HIV/AIDS research. TRY THE MAP to find out where Canadian HIV vaccine research is taking place.
|
|
Conferences
|
|
June 4 to 7, 2015
28th Annual CSI Conference
Winnipeg, Canada
|
|
June 9 to 12, 2015
7th SA AIDS Conference
Durban, South Africa
|
|
July 19 to 22, 2015
IAS 2015
8th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention
Vancouver, Canada
|
|
September 13 to 16, 2015
World STI & HIV 2015 Congress
Brisbane, Australia
|
|
November 30 to December 2, 2015
3rd International Conference on HIV/AIDS, STDs & STIs
Atlanta, USA
|
|
→
See full list of conferences
|
|
| |
|
Annual Update
|
|
|
Annual Update PDF
|
|
You are receiving this email because you registered to receive news updates from the Canadian HIV Vaccine Initiative (CHVI) Research and
Development Alliance Coordinating Office
or you are a member of a CHVI-funded
project team.
|
| |
|
Follow Us:
|
|
|
| |
| |
|
Address
|
|
ALLIANCE COORDINATING OFFICE
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com
|
|
| |
| |
|
About Us
|
|
The CHVI Research and Development Alliance Coordinating Office (ACO) was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.
|
|
| |
|
White Paper
|
The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.
|
|
Read more
|
|
|
|
| Production of this newsletter has been made possible through a financial contribution from the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.
Third-Party E-bulletin Disclaimer
This E-Bulletin contains links to third party websites ("Linked Sites"), which are not under the control of ACO and ACO is not responsible for the contents of any Linked Site, including any link contained in a Linked Site or any changes or updates to a Linked Site. The Linked Sites may not be available in French or English. ACO is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by ACO of the Linked Site or any association with its operators. We do not guarantee the accuracy of any information accessed through or published or provided by the Linked Site. You are responsible for viewing and abiding by the privacy statements and terms of use posted at the Linked Sites. Any specific comments or inquiries regarding the Linked Sites should be directed to the operator of the Linked Site.
|
|
|
Copyright © 2015
Canadian HIV Vaccine Initiative Research and Development Alliance Coordinating Office
|
|
|
The ACO E-Bulletin is deployed on behalf of the ACO by eTouchServices Inc..
162-2025 Corydon Ave. Suite 103 Winnipeg, MB R3P 0N5 Canada
|
|
|
